AstraZeneca PLC (AZN)vsZevra Therapeutics Inc. (ZVRA)
AZN
AstraZeneca PLC
$166.08
+1.22%
HEALTHCARE · Cap: $257.57B
ZVRA
Zevra Therapeutics Inc.
$11.67
+0.52%
HEALTHCARE · Cap: $689.45M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 44999% more annual revenue ($61.37B vs $136.07M). ZVRA leads profitability with a 42.8% profit margin vs 17.0%. AZN appears more attractively valued with a PEG of 1.19. ZVRA earns a higher WallStSmart Score of 63/100 (C+).
AZN
Buy60
out of 100
Grade: C+
ZVRA
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.2%
Fair Value
$195.81
Current Price
$166.08
$29.73 discount
Margin of Safety
+64.8%
Fair Value
$24.07
Current Price
$11.67
$12.40 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Keeps 43 of every $100 in revenue as profit
Strong operational efficiency at 42.3%
Revenue surging 53.3% year-over-year
Conservative balance sheet, low leverage
Every $100 of equity generates 27 in profit
Attractively priced relative to earnings
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Expensive relative to growth rate
Earnings declined 88.4%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : ZVRA
The strongest argument for ZVRA centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 42.8% and operating margin at 42.3%. Revenue growth of 53.3% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : ZVRA
The primary concerns for ZVRA are Market Cap, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while ZVRA is a growth play — different risk/reward profiles.
ZVRA carries more volatility with a beta of 0.95 — expect wider price swings.
ZVRA is growing revenue faster at 53.3% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
ZVRA scores higher overall (63/100 vs 60/100), backed by strong 42.8% margins and 53.3% revenue growth. AZN offers better value entry with a 15.2% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Zevra Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?